Evidence map›Paper›PMID 38636476›Full record

ArticleBlood purification2024

CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury.

Sevag Demirjian, Lakhmir Chawla, Danielle Davison, Lui G Forni, Michael Heung, Eric A J Hoste, Jay Koyner, J Patrick Kampf, Thomas Kwan, Paul McPherson and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood purification, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Sevag DemirjianDepartment of Kidney Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Lakhmir ChawlaDepartment of Medicine, Veterans Affairs Medical Center, San Diego, California, USA.
Danielle DavisonDepartments of Anesthesiology and Critical Care Medicine, George Washington University, Washington, District of Columbia, USA.
Lui G ForniDepartment of Intensive Care, Royal Surrey Hospital, Guildford, UK.
Michael HeungDivision of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Eric A J HosteIntensive Care Unit, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
Jay KoynerSection of Nephrology, University of Chicago, Chicago, Illinois, USA.
J Patrick KampfAstute Medical Inc. (a bioMérieux company), San Diego, California, USA.
Thomas KwanAstute Medical Inc. (a bioMérieux company), San Diego, California, USA.
Paul McPhersonAstute Medical Inc. (a bioMérieux company), San Diego, California, USA.
John A KellumCenter for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Astute Medical (United States) · USCleveland Clinic · USGeorge Washington University · USGhent University Hospital · BERoyal Surrey County Hospital · GBSan Francisco VA Medical Center · USUniversity of Chicago · USUniversity of Michigan · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAKI is a frequent complication of critical illness and portends poor outcome. CCL14 is a validated predictor of persistent severe AKI in critically ill patients. We examined the association of CCL14 with urine output within 48 h.

methodsIn pooled data from 2 studies of critically ill patients with KDIGO stage 2-3 AKI, CCL14 was measured by NEPHROCLEAR™ CCL14 Test on the Astute 140® Meter (low, intermediate, and high categories [1.3 and 13 ng/mL]). Average hourly urine output over 48 h, stage 3 AKI per urine output criterion on day 2, and composite of dialysis or death within 7 days were examined using multivariable mixed and logistic regression models.

resultsOf the 497 subjects with median age of 65 (56-74) years, 49% (242/497) were on diuretics. CCL14 concentration was low in 219 (44%), intermediate in 217 (44%), and high in 61 (12%) patients. In mixed regression analysis, hourly urine output over time was different within each CCL14 risk category based on diuretic use due to significant three-way interaction (p < 0.001). In logistic regression analysis, CCL14 risk category was independently associated with low urine output on day 2 per KDIGO stage 3 (adjusted for diuretic use and baseline clinical variables), and composite of dialysis or death within 7 days (adjusted for urine output within 48 h of CCL14 measurement).

conclusionsCCL14 measured in patients with moderate to severe AKI is associated with urine output trajectory within 48 h, oliguria on day 2, and dialysis within 7 days.

Indexed as

Acute Kidney InjuryOliguriaRenal DialysisAgedCritical IllnessFemaleHumansMaleMiddle AgedSeverity of Illness IndexAcute kidney injuryCCL14DialysisDiureticsOliguria

Identifiers

PMID38636476
PMCPMC11239143
OpenAlexW4394962601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.